SuicideNCT07864961
Expanding Access to Evidence-Based Suicide Risk Assessment and Intervention in a Crisis Stabilization Setting
A study testing Jaspr in people with Suicide and Suicide Attempt, run by Butler Hospital at 2 sites in United States.
Trial summary
The overarching goal of this project is to expand access to evidence-based suicide risk assessment, safety planning, and intervention among patients at elevated suicide risk by implementing Jaspr in a real-world psychiatric setting. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Suicide, Suicide Attempt, Randomized Controlled Trial (RCT)
- What is being tested?
- Jaspr
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 2 sitesUnited States
- Study dates
- 1 Oct 2026to 31 Oct 2027
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Aged 18 and older
- Able to read, write, and understand English well enough to complete study procedures
- Presence of past-month active suicidal ideation (i.e., Columbia Suicide Severity Rating Scale [C-SSRS] screener >1) and/or past three-month suicidal behavior, verified by the C-SSRS screener
- Owns a smartphone compatible with downloading the Jaspr-at-Home app
Who cannot join
- Medically or cognitively unable to participate in study procedures (e.g., current psychotic symptoms),
- Psychosocial factors influencing ability to complete study procedures (e.g., pending incarceration)
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States2 sites
Butler Hospital
Providence, Rhode Island, 02906
Gabriela Tolentino, 555-555-5555, GTolentino@carene.org
Heather Schatten, PhD
Brown University
Providence, Rhode Island, 02912
About this study
Official title: Expanding Access to Evidence-Based Suicide Risk Assessment and Intervention in a Crisis Stabilization Setting (Patient Informants and RCT)
The overarching goal of this project is to expand access to evidence-based suicide risk assessment, safety planning, and intervention among patients at elevated suicide risk by implementing Jaspr in a real-world psychiatric setting.
Read the detailed description
The overarching goal of this project is to expand access to evidence-based suicide risk assessment, safety planning, and intervention among patients at elevated suicide risk by implementing Jaspr in a real-world psychiatric setting: The Providence Center's Crisis Stabilization Unit (CSU), which provides short-term crisis care for adult patients in need of psychiatric or substance use disorder support as an alternative to, or step-down transition from, hospitalization. The investigators will conduct a pilot randomized controlled trial (N = 80) of Jaspr compared to CSU treatment as usual (TAU). In Phase 1, the investigators will conduct a formative evaluation to identify and address barriers prior to Jaspr implementation. The investigators will implement Jaspr in Phase 2, in which the investigators will randomize participants to either the Jaspr condition or TAU, collecting baseline and outcome data.
- Conditions
- Suicide, Suicide Attempt, Randomized Controlled Trial (RCT)
- Being tested
- Jaspr
- Medical subject headings
- Suicide, Suicide, Attempted
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
JasprBehavioural
Jaspr is a digital platform developed to "increase the delivery of suicide prevention evidence-based practices without adding to personnel needs in an effort to reduce suicidal behavior with an ultimate goal of saving lives." Jaspr includes the following evidence-based components: Comprehensive suicide assessment, crisis stability plans, and lethal means counseling, comfort and skills, and shared stories.
| Study group | Role | What they receive |
|---|---|---|
| Jaspr | Experimental | Jaspr is a digital platform developed to "increase the delivery of suicide prevention evidence-based practices without adding to personnel needs in an effort to reduce suicidal behavior with an ultimate goal of saving lives." Jaspr includes the following evidence-based components: Comprehensive suicide assessment, crisis stability plans, and lethal means counseling, comfort and skills, and shared stories. Receives: Behavioral: Jaspr |
| Treatment as Usual (TAU) | No intervention | Participants in this condition will receive research-related assessments but will not receive Jaspr. Instead, they will receive The Providence Center Crisis Stabilization Unit (CSU) services and post-discharge treatment as usual. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of evidence-based interventions received during crisis stabilization treatment
Group differences (treatment as usual [TAU] vs. Jaspr) in the number of received evidence-based interventions while receiving crisis stabilization treatment. This frequency will be derived from an aggregate of crisis stabilization plans, lethal means counseling, behavioral skills, and shared stories from people with lived experience. The greater the number, the more evidence-based interventions received.
Measured: From enrollment through discharge from the crisis stabilization unit (average length of stay is 5.7 days)
Thoroughness of evidence-based interventions received during crisis stabilization treatment
Group differences (treatment as usual [TAU] vs. Jaspr) in the thoroughness of evidence-based interventions while receiving crisis stabilization treatment. Thoroughness is derived from a 1 (not very thorough) to 5 (very thorough) scale, with higher numbers representing greater thoroughness. This number will be derived from the average thoroughness of four evidence-based interventions: crisis stabilization plans, lethal means counseling, behavioral skills, and shared stories from people with lived experience.
Measured: From enrollment through discharge from the crisis stabilization unit (average length of stay is 5.7 days)
Overall rating of care
Group differences in overall rating of the care received at the Crisis Stabilization Unit will be measured using a modified Emergency Room-Patient Satisfaction Survey, which assesses patients' overall satisfaction with the visit. This item is assessed on a 5-point rating scale (1=poor, 5=excellent).
Measured: Discharge from the crisis stabilization unit
Suicide-related coping
Measured with the Suicide-Related Coping Scale (SRCS), a 17-item self-report measure that examines patients' ability to cope with suicidal thoughts and urges. The SCRS uses a 5-point rating scale from 0=strongly disagree to 4=strongly agree. Thus, higher scores are associated with higher ability to cope with suicidal thoughts and urges.
Measured: From enrollment through discharge from the crisis stabilization unit (average length of stay is 5.7 days)
Intensity of emotional distress
The investigators will use the Safety and Imminent Distress Questionnaire (SIDQ) - Distress item, where 1=no distress and 10=highest distress ever felt. The SIDQ is based on the Keeping Myself Safe Usability Survey. The value used will be the change from enrollment to discharge.
Measured: From enrollment through discharge from the crisis stabilization unit (average length of stay is 5.7 days)
Extent to which participants felt calm or agitated
The investigators will use the Safety and Imminent Distress Questionnaire (SIDQ) - Agitation item, where 1=very calm and 10=very frustrated or agitated. The SIDQ is based on the Keeping Myself Safe Usability Survey. The value used will be the change from enrollment to discharge.
Measured: From enrollment through discharge from the crisis stabilization unit (average length of stay is 5.7 days)
Participants' ability to cope with thoughts of killing themselves
The investigators will use the Safety and Imminent Distress Questionnaire (SIDQ) - Coping ability item, where 1=no ability to cope and 10=strong ability to cope. The SIDQ is based on the Keeping Myself Safe Usability Survey. The value used will be the change from enrollment to discharge.
Measured: From enrollment through discharge from the crisis stabilization unit (average length of stay is 5.7 days)
Participants' readiness to go home
The investigators will use the Safety and Imminent Distress Questionnaire (SIDQ) - Readiness to go home item, where 1=not able and 10=very able. The SIDQ is based on the Keeping Myself Safe Usability Survey. The value used will be the change from enrollment to discharge.
Measured: From enrollment through discharge from the crisis stabilization unit (average length of stay is 5.7 days)
Suicidal ideation presence
The investigators will use the Columbia Suicide Severity Rating Scale (C-SSRS) screener at baseline (chart) and 12-week follow-up (clinical interview screener) to measure suicidal ideation presence. This will be coded as a 0=no suicidal ideation or 1=presence of suicidal ideation. The value used will be change from the month prior to enrollment to the month prior to the 12-week post-discharge follow-up assessment.
Measured: From enrollment to the end of the study at 12 weeks following discharge
Suicidal ideation severity
The investigators will use the Columbia Suicide Severity Rating Scale (C-SSRS) screener at baseline (chart) and 12-week follow-up (clinical interview screener) to measure suicidal ideation severity. This item is rated from 0 (no suicidal ideation) to 5 (suicidal ideation with intent and plan), with higher scores corresponding to greater suicidal ideation severity. The value used will be change from the month prior to enrollment to the month prior to the 12-week post-discharge follow-up assessment.
Measured: From enrollment to the end of the study at 12 weeks following discharge
Suicidal behavior composite
The investigators will use the Columbia Suicide Severity Rating Scale (C-SSRS) screener at baseline (chart) and 12-week follow-up (clinical interview screener) to measure suicidal behavior. Suicidal behavior will be calculated as a composite measure of presence of any suicidal behavior (actual, aborted, and interrupted attempts, preparatory behavior), where 0=no suicidal behavior and 1=suicidal behavior present. The value used will be change from the month prior to enrollment to the month prior to the 12-week post-discharge follow-up assessment.
Measured: From enrollment to the end of the study at 12 weeks following discharge
Readmissions/revisits
The investigators will examine the between groups differences in number of suicide-related ED visits, hospitalizations, and crisis services use during the 12-week follow-up period, measured using a modified Treatment History Interview.
Measured: From enrollment to the end of the study at 12 weeks following discharge
Secondary outcomes (10)
Overall rating of care received by Jaspr
Participants' overall rating of care received by Jaspr will be measured with an item from the Jaspr Health Patient Satisfaction Questionnaire ("Overall rating of care received by Jaspr"), which is on a scale of 1 (poor) to 5 (excellent). Higher scores represent a higher overall rating of care.
Measured: Discharge from the crisis stabilization unit
Extent to which providers and staff perceive the use of Jaspr as agreeable or satisfactory (acceptability)
Extent to which providers and staff perceive the use of Jaspr app in the Crisis Stabilization Unit (CSU) as agreeable or satisfactory. The investigators will use the Acceptability of Intervention Measure (AIM), a 4-item measure to determine whether an evidence-based practice is liked, appealing, welcomed and approved. The IAM is scored on a 5-point Likert scale (1 = completely disagree to 5 = completely agree), with higher scores indicating greater acceptability (range 4 through 20).
Measured: Through study completion, average of two years
Providers' and staff's perceived fit, relevance, or compatibility of Jaspr (appropriateness)
Providers' and staff's perceived fit, relevance, or compatibility of Jaspr app with the Crisis Stabilization Unit (CSU), and with their patient populations, measured by the Intervention Appropriateness Measure (IAM). The IAM is a 4-item measure to assess if an evidence-based practice is suitable, fitting, applicable and a good match with the particular setting. The IAM is scored on a 5-point Likert scale (1 = completely disagree to 5 = completely agree), with higher scores indicating greater appropriateness (range 4 through 20).
Measured: Through study completion, average of two years
Providers' and staff's perceived feasibility of Jaspr (feasibility)
Extent to which providers and staff feel that Jaspr app can be successfully used or carried out within the Crisis Stabilization Unit (CSU), measured by the Feasibility of Intervention Measure (FIM), a 4-item measure of how doable, easy to use, and implementable a practice is. The FIM is scored on a 5-point Likert scale (1 = completely disagree to 5 = completely agree), with higher scores indicating greater appropriateness (range 4 through 20).
Measured: Through study completion, average of two years
Amount of time Jaspr is used (reach)
Amount of time Jaspr is used (in minutes); data is collected from the Jaspr servers.
Measured: From enrollment through discharge from the crisis stabilization unit (average length of stay is 5.7 days)
Number of times Jaspr is accessed (reach)
Number of times Jaspr is accessed; data is collected from the Jaspr servers.
Measured: From enrollment through discharge from the crisis stabilization unit (average length of stay is 5.7 days)
Percent of Jaspr modules completed (reach)
Percent of Jaspr modules completed; data is collected from the Jaspr servers.
Measured: From enrollment through discharge from the crisis stabilization unit (average length of stay is 5.7 days)
Percent of Jaspr participants who activated Jaspr-at-Home companion app (reach)
Percent of participants in the Jaspr condition who also activated the Jaspr-at-Home companion app.
Measured: At the end of the study, 12 weeks following discharge
Number of providers and staff trained to use Jaspr (adoption)
The number of providers and staff trained to use and initiate Jaspr with participants.
Measured: Through study completion, average of two years
Adverse events associated with the use of Jaspr
Number of adverse events related to the use of Jaspr. This will be measured using an aggregate including death and participant self-report of life-threatening events, hospitalizations, and medical problems causing a persistent, significant disruption in ability to conduct one's normal life.
Measured: From enrollment to the end of the study at 12 weeks following discharge
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Oct 2026
- Study start1 Oct 2026 (estimated)
- Primary completion31 Oct 2027 (estimated)
- Study completion31 Oct 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SuicideStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Butler Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Brown University, The Providence Center
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07864961
- Sponsor's protocol ID
- BH-2339835
- Other IDs
- LSRG-1-154-24
- Status last verified
- Sep 2026
- First submitted
- 28 Sep 2026
- Last updated
- 8 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The following types of de-identified data will be shared: (1) demographic data, (2) clinical data, and (3) implementation outcome data. This includes data collected throughout the trial.